Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Cash from Financing Activities (2016 - 2025)

Orthopediatrics has reported Cash from Financing Activities over the past 10 years, most recently at -$417000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$417000.0 for Q4 2025, up 22.92% from a year ago — trailing twelve months through Dec 2025 was $24.0 million (down 54.88% YoY), and the annual figure for FY2025 was $24.0 million, down 54.88%.
  • Cash from Financing Activities for Q4 2025 was -$417000.0 at Orthopediatrics, down from -$282000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for KIDS hit a ceiling of $108.3 million in Q3 2022 and a floor of -$4.3 million in Q2 2024.
  • Median Cash from Financing Activities over the past 5 years was -$33500.0 (2021), compared with a mean of $11.0 million.
  • Peak annual rise in Cash from Financing Activities hit 390220.0% in 2024, while the deepest fall reached 1491.67% in 2024.
  • Orthopediatrics' Cash from Financing Activities stood at -$34000.0 in 2021, then decreased by 2.94% to -$35000.0 in 2022, then surged by 26920.0% to $9.4 million in 2023, then plummeted by 105.76% to -$541000.0 in 2024, then grew by 22.92% to -$417000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$417000.0 (Q4 2025), -$282000.0 (Q3 2025), and $24.8 million (Q2 2025) per Business Quant data.